Biogen Inc (NASDAQ: BIIB) and partner Eisai released data from the recent analysis of an ongoing long-term extension Phase 1b study of aducanumab, which evaluated patients with the pipeline candidate up to 36 months in the titration cohort and up to 48 months in the fixed-dose cohorts.

Assertio Settles Patent Litigation Against Purdue Pharma

Assertio Therapeutics Inc (NASDAQ: ASRT) announced said it has entered into a settlement agreement with Purdue Pharma with regard to its patent infringement lawsuit against the latter in a U.S. district court. The lawsuit alleges infringement by Purdue of some of Assertio's patents with regard to Purdue's commercialization of Oxycontin.

The agreement calls for Purdue paying a total of $62 million in cash.

Assertio's stock slid 4.37 percent to $7 in after-hours trading.

Novartis Unit Recalls Glaucoma Surgical Device

Novartis AG (ADR) (NYSE: NVS)'s Alcon unit announced an immediate, voluntary recall of its CyPass Micro-Stent from the global market, based on an analysis of five-year post-surgery data from the COMPASS-XT long-term safety study. The stent was approved by the FDA for use in conjunction with cataract surgery in adult patients, with mild-to-moderate primary open-angle glaucoma.

Emergent Biosolutions To Buy Narcan Nasal Spray Maker Adapt Pharma

Emergent Biosolutions announced a deal to buy Adapt Pharma along with its flagship product Narcan, or naloxone HCl Nasal Spray, which is a needle-free formulation of naloxone to treat known or suspected opioid overdose, for up to $735 million. The transaction value includes an upfront payment of $575 million and up to $100 million in cash for potential sales-based milestones through 2022.